US panel backs Sanofi-Aventis's Multaq
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis's anti-arrhythmic Multaq (dronedarone) should be approved for treating atrial fibrillation (AF), the USFDA's outside advisors said on March 18th. The cardiovascular-renal drugs advisory committee nevertheless favoured a narrow indication and said the label should not claim a mortality benefit.